UroGen narrows Teva patent case to single new patent as Zusduri drives $30.7M revenue jump

Filed May 6, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~2 min read

Key Changes

• high

  Company dismissed with prejudice its infringement claims on two original patents against Teva's generic, narrowing litigation to a single patent ('745) issued April 2025. Trial postponed to January 2027, three months before Jelmyto's orphan drug exclusivity expires in April 2027.

  Legal Proceedings verify on EDGAR →
• high

  Zusduri FDA approval in June 2025 drove Q1 2026 revenue to $51.0M, up $30.7M (152%) year-over-year. Operating loss narrowed $16.7M to $20.3M despite $10M increase in selling and marketing expenses for commercial expansion.

  MD&A: Revenue and Operating Results verify on EDGAR →
• high

  Refinanced debt with $250M Pharmakon facility in February 2026, drawing $200M at 8.25% fixed rate (down from SOFR+7.25%). Maturity extended to 2031 with principal repayment deferred to Q2 2030. Cash position declined $60M year-over-year to $140.3M.

  Risk Factors: Liquidity and Debt verify on EDGAR →